Abstract
To examine drug synergism between angiotensin II AT1-receptor blocker and Ca2+ channel blocker for lowering blood pressure (BP), telmisartan and lercanidipine were orally injected into to telemetered-spontaneous hypertensive rats and BP was monitored. The highest doses of both drugs (7.66 mg/kg of telmisartan and 1.92 mg/kg of lercanidipine) were clinically relevant at 80 and 20 mg human equivalent doses, respectively, and denoted as dose 1. After constructing the dose-response curve using 0 (vehicle-treated control), 1/16, 1/8, 1/4, 1/2 and 1 doses, all possible combinations of both drugs were tested. Drug synergism in combination therapy of telmisartan with lercanidipine was assessed by calculating the interaction index (γ) as evaluated by γ < 1. We found statistically significant drug synergism in the investigated (telmisartan: lercandipine) combinations of (1/8:1/4), (1/4:1) and (1/8:1). Our results suggest that the combination therapy of telmisartan and lercanidipine at lower doses are effective in lowering BP, and also reduce side effects caused by maximal doses of each drug. Therefore, drug combination of AT1-receptor blocker with Ca2+ channel blocker is a clinically important tool for the management of hypertension and hypertension-related cardiovascular risks.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Battershill, A. J. and Scott, L. J., Telmisartan: a review of its use in the management of hypertension. Drugs, 66, 51–83 (2006).
Benson, S. C., Pershadsingh, H. A., Ho, C. I., Chittiboyina, A., Desai, P., Pravenec, M., Qi, N., Wang, J., Avery, M. A., and Kurtz, T. W., Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension, 43, 993–1002 (2004).
Borghi, C., Lercanidipine in hypertension. Vasc. Health Risk Manag., 1, 173–182 (2005).
Chrysant, S. G., Melino, M., Karki, S., Lee, J., and Heyrman, R., The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin. Ther., 30, 587–604 (2008).
De Gasparo, M., Catt, K. J., Inagami, T., Wright, J. W., and Unger, T., International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev., 52, 415–472 (2000).
Griffiths, C. D., Morgan, T. O., and Delbridge, L. M. D., Effects of combined administration of ACE inhibitor and angiotensin II receptor antagonist are presented by a high NaCl intake. J. Hypertens., 19, 2087–2095 (2001).
Grote, K., Flach, I., Luchtefeld, M., Akin, E., Holland, S. M., Drexler, H., and Schieffer, B., Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species. Circ. Res., 92, e80–e86 (2003).
Guyton, A. C., Blood pressure control special role of the kidneys and body fluids. Science, 252, 1813–1816 (1991).
Inaba, S., Iwai, M., Tomono, Y., Senba, I., Furuno, M., Kanno, H., Okayama, H., Mogi, M., Higaki, J., and Horiuchi, M., Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists. Am. J. Hypertens., 22, 145–150 (2009).
Kota, B. P., Huang, T. H., and Roufogalis, B. D., An overview on biological mechanisms of PPARs. Pharmacol. Res., 51, 85–94 (2005).
Kurtz, T. W., Griffin, K. A., Bidani, A. K., Davisson, R. L., and Hall, J. E., Recommendation for blood pressure measurement in humans and experimental animals. Part 2: blood pressure measurement in experimental animals: a statement for professionals from the subcommittee of professional and public education of the American Heart Association council on high blood pressure research. Hypertension, 45, 299–310 (2005).
Lemmer, B., Arraj, M., Zuther, P., and Gorbey, S., Use of telemetry for research in cardiovascular chronobiology/chronopharmacology in rats and mice. European Chronobiology Telemetry User Group Meeting pp. Abstr 4 UK: Erl Wood Manor (2004).
Littlejohn, T. W. R., Majul, C. R., Olvera, R., Seeber, M., Kobe, M., Guthrie, R., and Oigman, W., Telmisartan plus amlodipine in patients with moderate or severe hypertension: Results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 × 4 factorial study. Postgrad. Med., 121, 5–14 (2009).
Martinez, M. L., Lopes, L. F., Coelho, E. B., Nobre, F., Rocha, J. B., Gerlach, R. F., and Tanus-Santos, J. E., Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J. Cardiovasc. Pharmacol., 47, 117–122 (2006).
Morgan, T. O., Brunner, H. R., Aubert, J. F., Wang, Q., Griffiths, C., and Delbridge, L., Cardiac hypertrophy depends upon sleep blood pressure: a study in rats. J. Hypertens., 18, 445–451 (2000).
Mourad, J. J., The evolution of systolic blood pressure as a strong predictor of cardiovascular risk and the effectiveness of fixed-dose ARB/CCB combinations in lowering levels of this preferential target. Vasc. Health Risk Manag., 4, 1315–1325 (2008).
Nagahama, S., Norimatsu, T., Maki, T., Yasuda, M., and Tanaka, S., The effect of combination therapy with an L/N-Type Ca(2+) channel blocker, cilnidipine, and an angiotensin II receptor blocker on the blood pressure and heart rate in Japanese hypertensive patients: an observational study conducted in Japan. Hypertens. Res., 30, 815–822 (2007).
Nelson, K. K. and Melendez, J. A., Mitochondrial redox control of matrix metalloproteinases. Free Radic. Biol. Med., 37, 768–784 (2004).
Okamoto, K. and Aoki, K., Development of a strain of spontaneously hypertensive rats. Jpn. Circ. J., 27, 282–293 (1963).
Okuda, N., Hayashi, T., Mori, T., Inamoto, S., Okabe, M., Mieno, S., Horimoto, H., and Kitaura, Y., Nifedipine enhances the cardioprotective effect of an angiotensin-II receptor blocker in an experimental animal model of heart failure. Hypertens. Res., 28, 431–438 (2005).
Oparil, S. and Weber, M., Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy. Postgrad. Med., 121, 25–39 (2009).
Philipp, T., Smith, T. R., Glazer, R., Wernsing, M., Yen, J., Jin, J., Schneider, H., and Pospiech, R., Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amolodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin. Ther., 29, 563–580 (2007).
Poldermans, D., Glazes, R., Kargiannis, S., Wernsing, M., Kaczor, J., Chiang, Y. T., Yen, J., Gamboa, R., and Fomina, I., Tolerability and blood pressure-lowering efficacy of the combination of almodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin. Ther., 29, 279–289 (2007).
Prandin, M. G., Cicero, A. F., Veronesi, M., Cosentino, E., Dormi, A., Strocchi, E., and Borghi, C., Persistence on treatment and blood pressure control with different first-line antihypertensive treatments: a prospective evaluation. Clin. Exp. Hypertens., 29, 553–562 (2007).
Ra, H. J. and Parks, W. C., Control of matrix metalloproteinase catalytic activity. Matrix Biol., 26, 587–596 (2007).
Schupp, M., Janke, J., Clasen, R., Unger, T., and Kintscher, U., Angiotensin type1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation, 109, 2054–2057 (2004).
Shin, C. Y., Choi, W. S., Yi, I., Nan, M. H., and Myung, C. S., Synergistic decrease in blood pressure by captopril combined with losartan in spontaneous hypertensive rats. Arch. Pharm. Res., 32, 955–962 (2009).
Tallarida, R. J., The interaction index: a measure of drug synergism. Pain, 98, 163–168 (2002).
Webb, R. L., Navarrete, A. E., Davis, S., and De Gasparo, M., Synergistic effects of combined converting enzyme inhibition and angiotensin II antagonism on blood pressure in conscious telemetered spontaneously hypertensive rats. J. Hypertens., 16, 843–852 (1998).
Witte, K., Engelhardt, S., Janssen, B. J., Lohse, M., and Lemmer, B., Circadian and short-term regulation of blood pressure and heart rate in transgenic mice with cardiac overexpression of the beta1-adrenoceptor. Chronobiol. Int., 21, 205–216 (2004).
Yue, H., Uzui, H., Shimizu, H., Nakano, A., Mitsuke, Y., Ueda, T., and Lee, J. D., Different effects of calcium channel blockers on matrix metalloproteinase-2 expression in cultured rat cardiac fibroblasts. J. Cardiovasc. Pharmacol., 44, 223–230 (2004).
Author information
Authors and Affiliations
Corresponding author
Additional information
These authors contributed equally to this work.
Rights and permissions
About this article
Cite this article
Lee, JJ., Shin, CY., Park, HJ. et al. Drug synergism of antihypertensive action in combination of telmisartan with lercanidipine in spontaneous hypertensive rats. Arch. Pharm. Res. 33, 1411–1418 (2010). https://doi.org/10.1007/s12272-010-0915-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-010-0915-9